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The current utility of bioluminescence imaging is constrained by a low photon yield that limits temporal
sensitivity. Here, we describe an imaging method that uses a chemiluminescent/ﬂuorescent protein,
ffLuc-cp156, which consists of a yellow variant of Aequorea GFP and ﬁreﬂy luciferase. We report an
improvement in photon yield by over three orders of magnitude over current bioluminescent systems.
We imaged cellular movement at high resolution including neuronal growth cones and microglial cell
protrusions. Transgenic ffLuc-cp156 mice enabled video-rate bioluminescence imaging of freely moving
animals, which may provide a reliable assay for drug distribution in behaving animals for pre-clinical
studies.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction energy transfer can improve bioluminescent probes, i.e., if a chemi-In live imaging, ﬂuorescent proteins such as Aequorea GFPs and
GFP-like proteins are widely used [1,2]. Recently, however, chemi-
luminescent proteins have also shown promise as powerful tools
for biological imaging [3–5]. The signiﬁcant advantages of biolumi-
nescence over ﬂuorescence imaging include a low background sig-
nal, the ability to observe luminescence without excitation light,
and the resultant preservation of delicate subcellular organelles
and structures during long term imaging protocols. However,
because of their weak luminescence, it is difﬁcult to use chemilu-
minescent proteins for optical imaging of cultured living cells or
in freely moving animals. With chemical and genetic modiﬁcations
of either proteins or substrates brighter and more diverse colors of
bioluminescent probes continue to be developed [6–9], including
the recently released NanoLuc (Promega). In addition, radiationlessY-NC-ND license. 
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energy can be used to induce the emission of an appropriately
positioned ﬂuorescent protein. For example, coupling a green-
emitting variant of Aequorea GFP to the calcium-sensitive photo-
protein aequorin (derived from Aequorea victoria) improves its
light emission properties. This protein, GFP-aequorin, has been
used to perform in vivo bioluminescence imaging of calcium sig-
naling in the brain of Drosophila [10]. Also, a yellow-emitting var-
iant of Aequorea GFP (EYFP) and the Renilla luciferase have been
concatenated to promote energy transfer from luciferase-bound
oxyluciferin to EYFP’s chromophore [11]. However, even these
new variants do not approach the temporal resolution needed for
adequate live imaging.
The fusion of a ﬂuorescent protein to a chemiluminescent pro-
tein may cause other effects, such as changes in stability or enzy-
matic activity that could in turn improve photon yield. In this
study, we explored the effect of these modiﬁcations by concatenat-
ing ﬁreﬂy luciferase (Luc2, Promega) with a yellow-emitting vari-
ant of Aequorea GFP. The resulting chimeric protein, ffLuc-cp156,
showed greatly improved performance in bioluminescence imag-
ing, allowing us to observe cultured cells and transgenic mice with
a high spatiotemporal resolution over extended periods of time
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does not overlap with the spectrum of Venus’s absorption, there
was no radiationless energy transfer between them. However,
the new probe created by the concatenation of Luc2 and the circu-
larly permuted Venus appears to have enhanced stability or enzy-
matic activity.
2. Material and methods
2.1. Construction of ffLuc
To generate the ffLuc construct, we inserted a restriction site
(GAATTC, EcoRI) between variants of Venus and ﬁreﬂy luciferase
(Luc2). The deletion mutant of Venus lacked 11 C-terminal ﬂexible
amino acids; the circularly permuted Venus had been interchanged
and reconnected by a short spacer between the original termini [12].
2.2. Measurement of bioluminescent spectra
The emission spectrum of each ffLuc construct, expressed in
HEK293T cells, was measured using a spectroscopic photometer
(F4500, Hitachi).
2.3. Relative intensities of the ffLuc bioluminescence
Bioluminescent signals of ffLuc-expressing HEK293T cells were
measured by photon counting in a Kronos instrument (ATTO). The
signal intensity was normalized to cell number.
2.4. Bioluminescence imaging of cultured cells expressing ffLuc-cp156
Transfection was performed using Lipofectamine 2000 transfec-
tion reagent; 4 lg of plasmid DNA was used for cells in a 35 mm
glass bottom dish. Transfected HeLa cells, microglial cells, or neu-
rons were observed using an inverted microscope (Olympus
IX71) with a 60 objective lens (N.A. 1.45), a 0.5 TV lens, and a
back-illuminated cooled CCD camera (Cascade512B, Roper Scien-
tiﬁc). The microglial cells and neurons were prepared from primary
cultures of rat brain. Prior to imaging, luciferin solution (Promega,
Beetle luciferin potassium salt) was added to the culture medium
at a ﬁnal concentration of 1 mM.
2.5. Animal experiments
The experimental procedures and housing conditions for ani-
mals were approved by the Institute’s Animal Experiments Com-
mittee and all the animals were cared for and treated humanely
in accordance with the Institutional Guidelines for Experiments
using Animals.
2.6. Bioluminescence imaging of mice using a digital camera
A luciferin solution (150 mg/kg) was administered intraperito-
neally to a CAG-ffLuc-cp156 transgenic mouse (5 months old).
Images were taken in a dark room using a common digital camera
(E-330, Olympus) with a 4 s exposure time, 3.5 F value, 1600 ISO
sensitivity, and 29.0 mm focal length.
2.7. Bioluminescence imaging of anesthetized CAG-ffLuc-cp156
transgenic mice
CAG-ffLuc-cp156 transgenic mice were anesthetized with a
mixture of isoﬂurane and oxygen. The mice received luciferin
(150 mg/kg BW) intravenously, intraperitoneally, or orally. Imme-
diately after luciferin administration, time-lapse or consecutivebioluminescence imaging was initiated, using the IVIS Imaging
System 100 Series (Xenogen, Alameda, CA).
2.8. Bioluminescence imaging of freely moving CAG-ffLuc-cp156
transgenic mice
Images of moving mice were taken using an in vivo imaging sys-
tem (LumazoneFA, Roper Japan) with a Cascade 512B cooled CCD
camera (Roper Scientiﬁc). Three administration methods were at-
tempted. First, luciferin (150 mg/kg) was administered to a mouse
intraperitoneally. Bioluminescent (BL) images were consecutively
collected every 33 ms. Second, luciferin was orally administered
voluntarily, as follows: a mouse was water-restricted for several
hours, then placed in the system along with 1.5% low-melting aga-
rose that contained luciferin (0.75 mg/mL). BL images (500 ms
exposure time) and ﬂuorescent (FL) images (100 ms exposure
time) were acquired in alteration; paired BL/FL images were ac-
quired every 5 s. Finally, luciferin was administered percutane-
ously: a mouse with a depilated back was placed in the system,
and vaseline containing 50 mg/g of luciferin powder was applied
to its back BL images (1 s exposure time) and FL images (100 ms
exposure time) were acquired in alternation; paired BL/FL images
were acquired every 5 s.
2.9. Visualization of CAG-ffLuc-cp156 embryos in the mother mouse
A wild-type female mouse was crossed with a CAG-ffLuc-cp156
transgenic male mouse (homozygous). The pregnant mouse was
given an intraperitoneal injection of luciferin (150 mg/kg BW); bio-
luminescence and ﬂuorescence images were captured by a cooled
CCD camera (PIXSIS-2048B, Roper Industries) with a lens of
50 mm focal length (EF50 mm, F1.2L USM, Canon). To take the ﬂuo-
rescence images, the mother mouse was illuminated with LEDs at
470 nm (Luxeon K2 LXK2-PB14-Q00, Lumileds), and the ﬂuores-
cence from the sample was detected via a band-pass ﬁlter
(ET535/30m, Chroma Technology).3. Results and discussion
3.1. Concatenation of Luc2 and Venus to yield ffLuc
A modiﬁed North American ﬁreﬂy Photinus pyralis luciferase,
codon-optimized for expression in human cells (Luc2, Promega),
was fused with Venus variants containing either a deletion or a ser-
ies of circular permutations [12] to create ffLuc-del or ffLuc-cps,
respectively (Fig. 1A). After transfection into cultured cells, the bio-
luminescent spectra of the constructs were measured with a spec-
trophotometer. The new ffLuc constructs showed nearly the same
emission spectra, peaking at 620 nm as Luc2 (Fig. 1B). However,
the bioluminescence intensities were higher in cells expressing
ffLuc constructs than in cells expressing Luc2. When quantitated
using a photon-counting device (Kronos, ATTO), cell samples con-
taining ffLuc-cp156 were several times brighter than samples con-
taining Luc2 (Fig. 1C). Normalization to protein expression level
revealed that bioluminescent activity per molecule is similar be-
tween ffLucs and Luc2 (Supplementary Fig. S1 online), but ffLucs
provided reliably brighter signals from both ﬂuorescence and bio-
luminescence. ffLuc-cp156 was used in further studies.
3.2. Visualization of bioluminescence in single cells using ffLuc-cp156
ffLuc-cp156 was transfected into cultured HeLa cells. After the
addition of luciferin (1 mM), we observed bioluminescent signals
from single cells using a standard ﬂuorescence microscope system
equipped with an oil-immersion objective lens and a
Bff Luc-del
ff Luc-cp144
ff Luc-cp156
ff Luc-cp172
ff Luc-cp194
700650600550500450400350
700650600550500450400350 700650600550500450400350 700650600550500450400350
700650600550500450400350700650600550500450400350
wavelength (nm) wavelength (nm) wavelength (nm)
wavelength (nm) wavelength (nm) wavelength (nm)
Lu
m
in
es
ce
nt
In
te
ns
ity
Lu
m
in
es
ce
nt
In
te
ns
ity
Lu
m
in
es
ce
nt
In
te
ns
ity
Lu
m
in
es
ce
nt
In
te
ns
ity
Lu
m
in
es
ce
nt
In
te
ns
ity
Lu
m
in
es
ce
nt
In
te
ns
ity
A gaattc luminescent intensity
(Photon count)
C
500 1000 1500 2000 2500 3000
Venus-del                  Luc2
cp144Venus       Luc2
cp156Venus       Luc2
cp172Venus       Luc2
cp194Venus       Luc2
ff Luc-cp156
ff Luc-del
Luc2
Luc2                                          ffLuc-del                                    ffLuc-cp144
ff Luc-cp156                               ffLuc-cp172                               ffLuc-cp194
Fig. 1. ffLuc constructs. (A) ffLuc was constructed as a fusion of a variant of Venus (a deletion mutant or a circularly permuted variant: cp144, cp156, cp172, and cp194) and
humanized ﬁreﬂy luciferase (Luc2). GAATTC, the restriction site (EcoRI). (B) Bioluminescent spectra of transfected cells. (C) Relative intensities of bioluminescence signals
from cells expressing ffLuc-cp156, ffLuc-del, and Luc2.
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the focus on cells using phase contrast (PC) images (Fig. 2A), and
then selected transfected cells using ﬂuorescence images (Fig. 2B).
Next, a 500 ms exposure of the camera yielded a bioluminescence
image wherein individual transfected cells were sufﬁciently re-
solved (Fig. 2C). When the camera exposure was extended to
5 s, the image quality was greatly improved (Fig. 2D). Further-
more, use of ffLuc-cp156 enabled us to capture a series of biolu-
minescence images of actively migrating microglial cells (Fig. 2E;
Supplementary Movie 1 online) and extending growth cones of
rat hippocampal neurons (Fig. 2F; Supplementary Movie 2 online)
over several consecutive hours. Although the exposure time could
be shortened to a few seconds while preserving image quality, we
adopted a 30 s exposure as a standard, in order to limit the total
amount of data collected over long-term imaging experiments.
Bioluminescent signals from cultured cells were sustained for
>2 days after the initial addition of luciferin, demonstrating theA B C D
FL BLPC
Fig. 2. Bioluminescence imaging of ffLuc-cp156 at the single-cell level. (A–D) Biolumine
inverted microscope (Olympus IX71) (A, phase contrast image; B, ﬂuorescence image; C
with 5 s camera exposure). (E and F) Bioluminescence images of a cultured microglial c
camera exposure. Scale bars, 10 lm. (For interpretation of the references to color in thipossibility of long-term in vivo observation of cell proliferation
and/or differentiation.
3.3. Strong bioluminescence from CAG-ffLuc-cp156 transgenic mice
To examine the utility of ffLuc-cp156 in living animals, we gen-
erated transgenic mice using a construct that consisted of a CAG
promoter-driven combination cassette bearing a neomycin-coding
sequence sandwiched by two loxP sequences and the ffLuc-cp156
gene (Fig. 3A). We cross-bred the line carrying the reporter gene
(CAG-neoloxP/loxP-ffLuc) with a line ubiquitously expressing Cre
recombinase (CAG-Cre mice) [13], to yield a mouse line ubiqui-
tously producing ffLuc-cp156. When illuminated with blue light,
the CAG-ffLuc-cp156 mice emitted yellow ﬂuorescence. After dis-
section, we investigated the ﬂuorescence of various organs and tis-
sues using a ﬂuorescence stereomicroscope. Fluorescence from
Venus was observed in almost all tissues examined, with theE F
BL BL BL
scence images of ffLuc-cp156 expressing HeLa cells. Images were acquired using an
, bioluminescence image with 500 ms camera exposure; D, bioluminescence image
ell (E) and neuronal growth cones (F, red arrow). Images were acquired with 30 s
s ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 3. Bioluminescence imaging using the ffLuc-cp156 transgenic mice. (A) Transgene of the ffLuc-cp156 reporter. (B–D) Bioluminescence images of anesthetized CAG-ffLuc-
cp156 transgenic adult mice. (B and C) Luciferin was administered intraperitoneally. Images were acquired using the IVIS system (B) and a common digital camera (C). (D)
Bioluminescence images of an anesthetized CAG-ffLuc-cp156 transgenic mouse that was given luciferin orally. BL, bioluminescence; FL, ﬂuorescence. left-most, ﬂuorescence
image. (E–G) Bioluminescence images of freely moving CAG-ffLuc-cp156 transgenic adult mice acquired using an in vivo imaging system (LumazoneFA, Roper Japan).
Bioluminescent signals are shown in red. (E) Intraperitoneal administration. Images were acquired at video rate (every 33 ms); see also Supplementary Movie 4. (F) Voluntary
oral administration. Camera exposure times for bioluminescence (red) and Venus ﬂuorescence (green) were 500 and 100 ms, respectively; see also Supplementary Movie 5.
(G) Percutaneous administration. Camera exposure times for bioluminescence (red) and Venus ﬂuorescence (green) were 1 s and 100 ms, respectively; see also
Supplementary Movie 6. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
C. Hara-Miyauchi et al. / Biochemical and Biophysical Research Communications 419 (2012) 188–193 191exception of spleen and red blood cells (Supplementary Fig. S2
online).
We examined the bioluminescence from an anesthetized
CAG-ffLuc-cp156 transgenic mouse (5 months old) in the dark
box of an IVIS system (Xenogen). Within 1 s after administration
of luciferin (150 mg/kg BW) through the tail vein, extremely strong
bioluminescence arose throughout the body, lasting for >6 h. Even
with the shortest exposure time of the system (500 ms), the biolu-
minescent intensity exceeded the camera’s saturation level. Next,
we performed intraperitoneal administration of luciferin
(150 mg/kg) on another anesthetized mouse (5 months old).
Although rapid and strong bioluminescence developed, we ac-
quired a bioluminescence image within the working range of the
system by placing the mouse as far as possible from the objective
(Fig. 3B). Bioluminescence was visible to the dark-adapted naked
eye, and the image could be acquired using an ordinary digital
camera (E-330, Olympus) (Fig. 3C). Considering the imaging
parameters of IVIS system described in previous reports, these
observations suggested that the overall bioluminescence of the
CAG-ffLuc-cp156 transgenic mouse was over three orders of mag-
nitude brighter than that of transgenic mice that expressed ﬁreﬂyluciferase (fLuc) under the control of the promoter/enhancer of the
major immediate-early gene of the human cytomegalovirus (CMV-
Luc) [14].
We also monitored the development of bioluminescence after
oral administration of luciferin to an anesthetized mouse. As soon
as a luciferin solution was injected into the mouth, strong biolumi-
nescence was observed from the stomach (Fig. 3D, 0 min). Initially
(<3 min), the stomach and intestine emitted stronger lumines-
cence than other body parts (Fig. 3D, 2 min). Subsequently, other
tissues in the trunk and limbs gradually became bioluminescent
(Fig. 3D, 10 min). The spatiotemporal patterns of the spreading bio-
luminescence are shown in Supplementary Movie 3 online. After
reaching saturation levels, these bioluminescent signals were
detectable for about 6 h.
3.4. Bioluminescence imaging of freely moving CAG-ffLuc-cp156
transgenic mice
Next, we performed bioluminescence imaging experiments
using awake mice. We used the in vivo imaging system
(LumazoneFA, Roper Japan), which allowed much shorter camera
high
low
right left right left
intensity
intensity
BL FL
Fig. 4. Bioluminescence imaging of embryos in a pregnant mouse. Bioluminescent
(BL) and ﬂuorescent (FL) images of a pregnant wild-type mouse carrying CAG-ffLuc
transgenic embryos.
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(150 mg/kg BW), we successfully visualized bioluminescence in a
freely moving CAG-ffLuc-cp156 mouse at video-rate (33 ms expo-
sure time) (Fig. 3E; Supplementary Movie 4 online). The biolumi-
nescence from the mouse’s body was bright enough to visibly
illuminate the inside of the box.
We next studied oral administration of luciferin. A thirsty
mouse was placed in a dark box containing wet agarose containing
luciferin. After the mouse chewed the agarose, both sides of the
abdomen began glowing (Fig. 3F; Supplementary Movie 5 online).
Using CMV-Luc, Hiler et al. showed that voluntary drinking of lucif-
erin resulted in a similar spatial pattern of luminescence to that
was achieved by intravenous luciferin administration [15]. In com-
parison to this earlier study, CAG-ffLuc-cp156 mice enabled imme-
diate detection of drinking and analysis of the rapid kinetics of
absorption which may allow its use in drug distribution studies
in awake animals.
Finally, we examined whether we could visualize luciferin
penetration through the skin. Immediately after attachment of a
luciferin-containing Vaseline poultice to the back, the skin started
to emit bioluminescent signals (Fig. 3G; Supplementary Movie 6
online). The luminescent signals appeared ﬁrst as dots, and then
expanded to cover the whole area of treated skin. These signals re-
mained on the body surface during the observation time period
(1 h), despite the ubiquitous expression of ffLuc-cp156, suggest-
ing that the luciferin did not penetrate deeper into the body.
It is possible to administer luciferin in different ways to CAG-
ffLuc-cp156 transgenic mice, which ubiquitously express ffLuc-
cp156, in order to observe spatiotemporal patterns in the develop-
ment of bioluminescence, i.e., the build-up of oxyluciferin. We be-
lieve that these approaches will provide reliable readouts of
absorption and inﬁltration of drugs in conscious animals. Impor-
tant applications would include real-time analysis of uptake and
bioactivatable cleavage of luciferin-transporter conjugates [16]. It
should be noticed that one shot of luciferin (150 mg/kg BW) caused
intense and long-lasting (>4 h) bioluminescent signals. Further-
more, the CAG-ffLuc-cp156 mice were tolerant to repeated biolu-
minescence imaging experiments; one mouse continued to look
healthy after being subjected to three consecutive experiments
over a few days. It is thus unlikely that high levels of biophotonic
activity have grave, negative effects on animal physiology [17].
3.5. Labeling CAG-ffLuc-cp156 embryos in pregnant mice
The strong bioluminescence from ffLuc-cp156 in transgenic
mouse embryos in utero could be detected outside their mother’s
body. We crossed a wild-type female mouse with a CAG-ffLuc-
cp156 transgenic male mouse carrying two copies of the ffLuc-
cp156 gene. Luciferin was administered intraperitoneally (150 mg/
kgBW) to themothermouse at a late stage of pregnancy. Thehetero-
zygous embryos could be clearly identiﬁed as discrete objects with
low background in bioluminescence images, although individual
embryos were not fully resolved (Fig. 4, BL). By contrast, these em-
bryos were not identiﬁable in ﬂuorescence images (Fig. 4, FL). Thus,
our bioluminescence imaging system can be used to non-invasively
monitor gestation states.
3.6. Neuronal stem/precursor cells from CAG-ffLuc-cp156 transgenic
mice
We investigated whether bright cell populations could be ob-
tained from CAG-ffLuc-cp156 transgenic mice. We prepared neuro-
nal stem/precursor cells (NS/PCs) from CAG-ffLuc-cp156 transgenic
mice according to established methods [18] and counted photons
per second (photon/s) emitted from cultured cells using the IVIS
system. The photon/s measurements increased linearly with thenumber of cells (Supplementary Fig. S3A online); 1  104 cells
yielded approximately 1  107 photon/s. As a comparison, we per-
formed the same NS/PC preparation and quantiﬁcation using the
widely-used transgenic mouse line, CMV-Luc, in which fLuc is ex-
pressed ubiquitously [15]; in this case, 1  104 cells from CMV-Luc
mice produced only 7  104 photon/s (Supplementary Fig. S3B on-
line). Thus, NS/PCs from CAG-ffLuc-cp156 mice produce >10,000
times more photons per unit time than those from CMV-Luc mice.
NS/PCs can be maintained in vitro as cell aggregates, called
neurospheres that can be used for cell transplantation experiments
and therapies. To assay the utility of bioluminescence in a trans-
plantation preparation, we prepared neurospheres from
CAG-ffLuc-cp156 mice and veriﬁed the even distribution of Venus
ﬂuorescence in each sphere (Supplementary Fig. S4A online). We
then transplanted the cells into the injured spinal cord of a wild-
type mouse. In situ survival of the labeled cells was veriﬁed by
bioluminescence imaging 1 and 2 weeks after transplantation
(Supplementary Fig. S4B and C online).
3.7. Visualization of the neural crest lineage-speciﬁc expression of
ffLuc-cp156
Via genetic manipulation, it is possible to express ffLuc-cp156 in
speciﬁc cell-types or tissues. To visualize the neural crest-derived
cells, the ffLuc-cp156 reporter mice were crossed with transgenic
mice expressing Cre recombinase under the control of either the
Wnt1 promoter/enhancer [19] or the P0 promoter [20] to
yield Wnt1/ffLuc-cp156 (Supplementary Fig. S5A online) and
P0/ffLuc-cp156 (Supplementary Fig. S5B online), respectively. After
intraperitoneal administration of luciferin (150 mg/kg BW), biolu-
minescent signals were observed exclusively in the neural crest-
derived cells of neonatal mice, mostly in the cephalic region,
reﬂecting the endogenous gene expression of pattern of Wnt1
and P0 genes [21]. These results highlight the effectiveness of
ffLuc-cp156 reporter mice for imaging speciﬁc cell populations in
intact awake animals that may be bred with different Cre trans-
genic mouse lines to achieve cell type, tissue-speciﬁc visualization
of bioluminescence and ﬂuorescence.
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